Dr. Michael Poulter, CSO of OB Pharmaceuticals to present at Eilat XIV.

LONDON, ONTARIO May 2, 2018 — OB Pharmaceuticals was invited to present the details of its drug development program of oxynytones at the 14th Eilat Conference in Madrid, Spain May 13-16, 2018. Dr. Michael Poulter will discuss the unique differentiating properties of these novel compounds and the compelling preclinical evidence in support of their continued development as promising therapeutics for the treatment of epilepsy and other related seizure disorders.

About Eilat XIV
The Eilat Conference on New Antiepileptic Drugs and Devices will take place from 13th May to 16th May 2017 at the Melia Castilla Hotel & Convention Center in Madrid, Spain. The conference will cover areas like designed to provide an in-depth progress report on new antiepileptic drugs in various stages of development, as well as to present new findings on second-generation treatments. For more information: https://www.eilatxiv.com

About OB Pharmaceuticals
OB Pharmaceuticals is an early stage biopharmaceutical company dedicated to improving the lives of individuals through the development of first-in-class therapeutics for more effective prevention and management of epilepsy and other related seizure disorders.

Leave a Reply

Your email address will not be published. Required fields are marked *